2019年国家自然科学基金委员会按照新时代科学基金"鼓励探索,突出原创;聚焦前沿,独辟蹊径;需求牵引,突破瓶颈;共性导向,交叉融通"的资助导向,试点开展基于科学问题属性的分类申请与评审工作.本文分析了参与分类评审试点工作中申请项目数量最多的医学科学部临床肿瘤学科面上项目的分类评审试点工作情况,探讨了对四类科学问题属性的具体内涵的理解和试点工作实施过程中遇到的问题,旨在为新时代科学基金资助导向的深化改革提供参考.

The morbidity of pancreatic ductal adenocarcinoma (PDAC) has been increasing over years, while the treatment efficacy and prognosis of PDAC remain far from satisfying. The newly-ermerged tumor immunotherapy has not only made lots of breakthroughs in various malignancies, but also brought an opportunity to the treatment of pancreatic cancer.PDAC immunotherapies, mainly including vaccine therapy, adoptive T cell thanfer therapy, checkpoint blockade therapy, have achieved a certain effect, however, the clinical outcomes have not been satisfactory. Therefore, the combination of immunotherapies based on different theoretical views is important and is likely to be the trend in the future. Carcinoma associated fibroblast (CAF) is the most common cell in pancreatic cancer stromal component. It will be helpful to develop more potential therapeutic targets by further exploring CAF and the mechanism of fibrosis mediated immunosuppression.